Alnylam Pharmaceuticals
ALNY
#1034
Rank
C$31.73 B
Marketcap
C$236.93
Share price
-2.42%
Change (1 day)
-64.71%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): C$1.56 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are C$4.80 Billion. In 2025 the company made an earning of C$0.90 Billion, an increase over its 2024 earnings that were of -C$0.33 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) C$1.56 B72.67%
2025 C$0.90 B-375.96%
2024 -C$0.33 Billion-24.59%
2023 -C$0.44 Billion-67.84%
2022 -C$1.36 Billion36.93%
2021 -C$0.99 Billion-8.04%
2020 -C$1.08 Billion-15.66%
2019 -C$1.28 Billion12.23%
2018 -C$1.14 Billion62.91%
2017 -C$0.7 Billion17.78%
2016 -C$0.6 Billion43.44%
2015 -C$0.42 Billion60.69%
2014 -C$0.26 Billion98.2%
2013 -C$0.13 Billion
2011 -C$76.5 Million27.48%
2010 -C$60.01 Million-10.92%
2009 -C$67.36 Million95.77%
2008 -C$34.41 Million
2006 -C$55.12 Million-9.13%
2005 -C$60.67 Million34.74%
2004 -C$45.03 Million36.79%
2003 -C$32.92 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
C$21.65 B 1,280.17%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$9.99 B 536.67%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
C$7.20 B 359.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-C$0.19 Billion-111.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-C$66.19 Million-104.22%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-C$0.12 Billion-107.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
C$2.23 B 42.71%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-C$0.23 Billion-114.18%๐Ÿ‡บ๐Ÿ‡ธ USA